Home LiteratureArticle Details
PMID: 19506300 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells.

Blood ·Vol. 114 ·No. 10 ·2009-09-03 ·Pages 2197-206

Shao ES, Lin L, Yao Y, Boström KI

Abstract

Expression of vascular endothelial growth factor (VEGF) is tightly regulated to achieve normal angiogenesis. The objective was to examine regulation of VEGF by the activin-like kinase receptors (ALKs) ALK1 and ALK5. Transforming growth factor beta1 (TGFbeta1) and bone morphogenetic protein-9 (BMP-9) enhanced and suppressed VEGF expression, respectively, in aortic endothelial cells, as determined by real-time polymerase chain reaction, immunoblotting, cell proliferation, and tube formation. The use of small interfering RNA revealed that TGFbeta1 stimulated VEGF expression by activating ALK5, TGFbeta type II receptor, and SMAD2, whereas BMP-9 suppressed it by activating ALK1, BMP type II receptor, and SMAD1. ALK1 signaling occurred independently of ALK5 activity. Partial ALK1 deficiency in vitro and in vivo resulted in elevated VEGF expression. In vitro, increased BMP-9 levels normalized VEGF expression in cells with partial, but not severe, ALK1 deficiency. Time course experiments revealed that an increase in ALK1 expression induced by BMP-4, an angiogenic stimulus, preceded induction of ALK5 and VEGF in control cells. In ALK1-deficient cells, however, VEGF expression occurred earlier and was abnormally high, even though ALK5 was not induced. Our results suggest that ALK1 and ALK5 are both essential for correct regulation of VEGF, and that disruption of either pathway leads to disease.

MeSH Terms
Activin Receptors, Type II/genetics,metabolism Animals Bone Morphogenetic Protein 4/genetics,metabolism Cattle Cells, Cultured Endothelial Cells Enzyme Activation/physiology Gene Expression Regulation/physiology Growth Differentiation Factor 2 Growth Differentiation Factors/genetics,metabolism Humans Protein Serine-Threonine Kinases/genetics,metabolism RNA, Small Interfering/genetics Receptor, Transforming Growth Factor-beta Type I Receptors, Transforming Growth Factor beta/genetics,metabolism Time Factors Transforming Growth Factor beta1/genetics,metabolism Vascular Endothelial Growth Factor A/biosynthesis,genetics
Chemicals
BMP4 protein, human Bone Morphogenetic Protein 4 GDF2 protein, human Growth Differentiation Factor 2 Growth Differentiation Factors RNA, Small Interfering Receptors, Transforming Growth Factor beta Transforming Growth Factor beta1 VEGFA protein, human Vascular Endothelial Growth Factor A Protein Serine-Threonine Kinases ACVRL1 protein, human Activin Receptors, Type II Receptor, Transforming Growth Factor-beta Type I TGFBR1 protein, human
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Shao Esther S
Division of Cardiology, David Geffen School of Medicine, University of California-Los Angeles, CA 90095-1679, USA.
Lin Laura
Yao Yucheng
Boström Kristina I
References (45)
45 references, click to expand
  1. KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1.
    Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):532-9 PMID: 17194892
  2. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2.
    Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2266-74 PMID: 18948634
  3. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.
    J Clin Invest. 2004 Feb;113(4):516-27 PMID: 14966561
  4. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.
    Am J Pathol. 2001 Mar;158(3):1145-60 PMID: 11238063
  5. Regression of pulmonary arteriovenous malformations after transcatheter reconnection of the pulmonary arteries in patients with unidirectional Fontan.
    Congenit Heart Dis. 2007 May-Jun;2(3):179-84 PMID: 18377462
  6. Modification of the Fontan procedure. Superior vena cava to left pulmonary artery connection and inferior vena cava to right pulmonary artery connection with adjustable atrial septal defect.
    Circulation. 1995 Jun 15;91(12):2943-7 PMID: 7796504
  7. Pulmonary AV malformations after superior cavopulmonary connection: resolution after inclusion of hepatic veins in the pulmonary circulation.
    Ann Thorac Surg. 1997 Apr;63(4):960-3 PMID: 9124971
  8. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.
    Cell. 1993 Nov 19;75(4):671-80 PMID: 8242742
  9. Transforming growth factor-betas and vascular disorders.
    Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1712-20 PMID: 16675726
  10. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2.
    Blood. 2008 Jan 15;111(2):633-42 PMID: 17911384
  11. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
    J Biol Chem. 1994 Mar 4;269(9):6271-4 PMID: 8119973
  12. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects.
    Curr Pharm Des. 2006;12(10):1173-93 PMID: 16611099
  13. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis.
    Circ Res. 2008 Oct 10;103(8):804-12 PMID: 18787191
  14. A rapid and sensitive bioassay to measure bone morphogenetic protein activity.
    BMC Cell Biol. 2007 Sep 19;8:41 PMID: 17880711
  15. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis.
    Int J Cancer. 2002 Jan 10;97(2):142-8 PMID: 11774256
  16. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density.
    Int J Mol Med. 2005 Jan;15(1):15-9 PMID: 15583822
  17. Pattern formation by vascular mesenchymal cells.
    Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9247-50 PMID: 15197273
  18. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2.
    Hum Mol Genet. 2003 Mar 1;12(5):473-82 PMID: 12588795
  19. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells.
    Circ Res. 2000 Sep 15;87(6):516-21 PMID: 10988245
  20. Pulmonary vascular disorders in portal hypertension.
    Eur Respir J. 1998 May;11(5):1153-66 PMID: 9648972
  21. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
    Circ Res. 2008 Apr 25;102(8):914-22 PMID: 18309101
  22. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.
    Blood. 2007 Mar 1;109(5):1953-61 PMID: 17068149
  23. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2.
    J Biol Chem. 2002 Feb 8;277(6):4388-94 PMID: 11741887
  24. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes.
    Kidney Int. 2002 Sep;62(3):901-13 PMID: 12164872
  25. Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.
    J Biol Chem. 1999 Apr 9;274(15):9984-92 PMID: 10187774
  26. Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells.
    Cardiovasc Res. 2007 May 1;74(2):279-89 PMID: 17074310
  27. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.
    Development. 2002 Jun;129(12):3009-19 PMID: 12050147
  28. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis.
    Trends Cardiovasc Med. 2003 Jul;13(5):169-75 PMID: 12837578
  29. Arteriovenous malformations in mice lacking activin receptor-like kinase-1.
    Nat Genet. 2000 Nov;26(3):328-31 PMID: 11062473
  30. Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development.
    Lab Invest. 2006 Feb;86(2):116-29 PMID: 16344855
  31. Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures.
    Wien Klin Wochenschr. 2006 Mar;118(3-4):72-80 PMID: 16703249
  32. Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension.
    Pathol Int. 2000 Jun;50(6):472-9 PMID: 10886723
  33. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells.
    Endocrinology. 2002 Oct;143(10):3759-65 PMID: 12239085
  34. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4.
    Circ Res. 2008 May 9;102(9):1065-74 PMID: 18369157
  35. Altered endothelial gene expression associated with hereditary haemorrhagic telangiectasia.
    Eur J Clin Invest. 2007 Jul;37(7):580-8 PMID: 17576210
  36. Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells.
    J Biol Chem. 2004 Dec 17;279(51):52904-13 PMID: 15456771
  37. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31 PMID: 10716993
  38. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development.
    J Biol Chem. 2007 Oct 12;282(41):30131-42 PMID: 17670744
  39. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression.
    Haematologica. 2005 Jun;90(6):818-28 PMID: 15951295
  40. Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver.
    J Biol Chem. 2000 Jun 16;275(24):17937-45 PMID: 10849432
  41. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling.
    Mol Cell. 2003 Oct;12(4):817-28 PMID: 14580334
  42. Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos.
    Biochem Biophys Res Commun. 2005 Apr 1;329(1):324-30 PMID: 15721310
  43. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
    J Cell Sci. 2007 Mar 15;120(Pt 6):964-72 PMID: 17311849
  44. Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling.
    Physiol Genomics. 2005 May 11;21(3):396-403 PMID: 15769904
  45. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1.
    J Biol Chem. 2006 Nov 10;281(45):33921-30 PMID: 16950789
Article Info
Journal
Blood
Abbr.
Blood
ISSN
1528-0020
Published
2009-09-03
Epub
2009-00-08
Pages
2197-206
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC2744576
Subset
IM
Grants
NHLBI NIH HHS · P01 HL030568 · United States
NHLBI NIH HHS · R01 HL081397 · United States
NHLBI NIH HHS · HL30568 · United States
NHLBI NIH HHS · HL81397 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com